newsfilter
← Latest News
GlobeNewswire·

Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year -- Continued Progress on the Rare Disease Nontuberculous Mycobacteria